Metabolomics allows the simultaneous, quantitative analysis of thousands of different metabolites within a given sample (Mamas et al. 2010; this issue) . It aims at identifying unique fingerprints of specific disturbances, for example diseases or effects of exposure to toxic compounds. The metabolome has been claimed to be the ''best indicator of an organism's phenotype'' (Blow 2008) . David Wishart, member of the Human Metabolome Project, gave an example of a man holding his breath for some minutes. While genomic or proteomic analysis can not give any evidence of stress even if the person turns blue, metabolomics will indicate dramatic changes (Blow 2008) .
On the other hand, we observe a high degree of popularity of RNA profiling (Bolt et al. 2010; Glahn et al. 2008; Lee et al. 2010; Godoy et al. 2009; Schug et al. 2008; Shimada et al. 2010; Stapleton and Chan 2009; Davidson et al. 2009; Rand et al. 2010 ) for characterization of actions of toxic compounds, whereas publication of systematic metabolomic studies has been rare in our journal.
In clinical practise it is routine to measure certain biomarkers, such as bilirubin, serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) to diagnose liver disease. To which degree can metabolomics really improve the current state in clinical diagnosis and in identification of drug toxicity? One of the largest studies was performed by the Consortium for Metabonomic Toxicology. Predictive models based upon NMR spectra of rodent urine and serum demonstrated that liver and kidney toxicity can be predicted with sensitivities of 41 and 67% and specificities of 100 and 77% (review: Beger et al. 2010; Ebbels et al. 2007 ). Biomarker research in combination with in vitro systems and mathematical modelling is one of the cutting-edge topics in toxicology (Read et al. 2010; Payan et al. 2009; Devi et al. 2007; Hewitt et al. 2007; Höhme et al. 2007 Höhme et al. , 2010 Carmo et al. 2006 Carmo et al. , 2007 Kafert-Kasting et al. 2006; Elcombe et al. 2010) . Therefore, the editors are grateful that M. Mamas, W. Dunn, L. Neyses and R. Goodacre of the University of Manchester now contribute a review about the establishment of metabolomics biomarkers in various diseases, including metabolic and cardiovascular disease, as well as cancer. This is a must-read for everybody interested in metabolomics. 
